Vienna, November 3–5, 2025
Biogenera will take part in BIO-Europe 2025, Europe’s premier event for business development and strategic partnering in the biotech and pharmaceutical industries, to be held in Vienna from November 3 to 5, 2025.
Representing the company will be Massimiliano Cesarini, CEO & Chairman, and Federico Ragni, Head of Business Development, who will meet with international companies, investors, and institutions from across the life sciences sector.
Organized by Informa Connect, BIO-Europe is widely recognized as one of the world’s most influential conferences for fostering new collaborations, licensing agreements, and strategic partnerships across the biotech and pharma ecosystem.
Throughout the three-day event, Biogenera will present the latest developments on BGA002, its first-in-class anti-gene drug candidate developed to treat aggressive pediatric and adult cancers driven by the overexpression of the MYCN oncogene.
At the same time, the company aims to strengthen its international network and explore new scientific and financial partnerships to support the growth of its next-generation anti-gene drug pipeline.
Biogenera’s participation in BIO-Europe 2025 marks another milestone in the company’s internationalization path, reinforcing its position as a leading innovator in the global biotechnology landscape.
English 
Italian